BRCA1 and breast carcinoma: Prexasertib has showed moderate clinical efficacy in a phase 2 trial on BRCA1/2-mutated breast cancer and sporadic TNBC is ongoing; 1 of 9 patients reached PR and 4 of 9 attained stable disease [196, 197].